Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
This page aggregates historical and ongoing news coverage related to the ticker symbol LIFE, which historically represented aTyr Pharma, Inc. on the Nasdaq Capital Market. aTyr describes itself as a clinical stage biotechnology company developing first-in-class medicines from a proprietary tRNA synthetase platform, with a focus on fibrosis and inflammation. Company news has highlighted scientific progress, clinical milestones, and corporate developments tied to this strategy.
Readers can expect news items covering aTyr’s lead therapeutic candidate, efzofitimod, a biologic immunomodulator in clinical development for interstitial lung disease. Press releases have described key events such as Phase 3 EFZO-FIT™ trial updates in pulmonary sarcoidosis, Phase 2 EFZO-CONNECT™ enrollment in systemic sclerosis-related interstitial lung disease, and independent data and safety monitoring board reviews recommending continuation of the EFZO-FIT™ study without modification. Scientific conference presentations, including posters detailing efzofitimod’s mechanism of action through neuropilin-2 and its effects on myeloid cells, also feature prominently.
In addition to clinical and scientific updates, the news stream includes corporate communications such as quarterly results, pipeline summaries, and the announcement of the Nasdaq ticker change from LIFE to ATYR. These releases provide context on how aTyr is advancing its tRNA synthetase-based discovery platform, managing its clinical portfolio, and communicating with the investment community.
For investors, researchers, and clinicians following aTyr, the LIFE news archive offers a structured view of how the company’s programs have evolved over time. By reviewing these items, users can trace the development of efzofitimod in interstitial lung disease, observe the company’s engagement with scientific and investor conferences, and understand the rationale behind the transition from the LIFE ticker to ATYR. Bookmark this page to access a consolidated history of company announcements associated with the LIFE symbol.
aTyr Pharma announced that its partner Kyorin Pharmaceutical has completed the final subject visit in the Phase 1 clinical trial of ATYR1923, triggering a milestone payment to aTyr. The trial evaluated safety and pharmacokinetics in 32 healthy Japanese male volunteers and aims to initiate patient trials for interstitial lung disease in Japan. Kyorin's progress with ATYR1923 is encouraging for aTyr, which is also conducting a Phase 1b/2a trial for pulmonary sarcoidosis and has previously tested ATYR1923 in COVID-19 patients.
aTyr Pharma (Nasdaq: LIFE) has announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 AM ET and will be accessible on the company's website for 90 days post-event. Additionally, the company will engage in virtual one-on-one meetings during the J.P. Morgan Healthcare Conference week (January 11-15, 2021), facilitated by the Biotechnology Innovation Organization.
aTyr Pharma announced positive topline results from its Phase 2 trial of ATYR1923 in hospitalized COVID-19 patients. The study met its primary safety endpoint with ATYR1923 being well-tolerated at doses of 1.0 and 3.0 mg/kg. Notably, patients receiving the 3.0 mg/kg dose demonstrated a median recovery time of 5.5 days, and 83% recovered in less than a week. The trial involved 32 patients and assessed safety and preliminary efficacy against a placebo. The company plans to provide further insights during a conference call on January 4.
aTyr Pharma (Nasdaq: LIFE) has announced the completion of target enrollment in its Phase 1b/2a clinical trial for ATYR1923, aimed at treating pulmonary sarcoidosis, with 36 patients enrolled. Results are anticipated in Q3 2021, potentially guiding future studies in interstitial lung diseases (ILD). ATYR1923 targets immune modulation to improve lung function with reduced toxicity compared to existing treatments. Additionally, a Phase 2 trial for COVID-19 patients has completed enrollment, with topline data expected soon.
aTyr Pharma has completed enrollment in its Phase 2 trial of ATYR1923 for COVID-19 patients, expecting topline data soon. The company is advancing its oncology pipeline with the new candidate ATYR2810 and has ongoing collaborations for research development. Financially, aTyr reported revenues of $0.1 million for Q3 2020, compared to $0.2 million in Q3 2019. R&D expenses rose to $4.6 million, reflecting increased clinical activities. As of September 30, 2020, cash and investments totaled $36.1 million, following the repayment of $3.1 million in loans.
On November 11, 2020, aTyr Pharma (Nasdaq: LIFE) announced a publication of a peer-reviewed paper demonstrating advancements in its antibody program. The research, conducted in collaboration with AbCellera Biologics, highlights methods for isolating and engineering human antibodies with high target affinity. Utilizing its tRNA synthetase biology platform, aTyr aims to create new biologics to modulate therapeutic pathways. The findings have already contributed to the development of antibody candidates for targeting Neuropilin-2, enhancing aTyr's pipeline for future therapeutic applications.
aTyr Pharma (Nasdaq: LIFE) has identified receptor targets for two tRNA synthetases, paving the way for new therapies targeting cancer and fibrosis. This discovery is significant as it enhances understanding of extracellular tRNA synthetases' roles in disease and informs future drug development. The findings were achieved through collaboration with CSL Behring. CEO Sanjay Shukla highlighted this as a major milestone in their drug discovery efforts.
aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, is set to report its third quarter 2020 financial results and provide a corporate update on November 12, 2020, after market close. The company is focused on the discovery and development of innovative medicines utilizing novel biological pathways, particularly through its lead product candidate, ATYR1923, aimed at treating inflammatory lung diseases. A conference call and webcast will take place on the same day at 5:00 p.m. EST.
aTyr Pharma announced a research collaboration with the Medical University of South Carolina to advance its neuropilin-2 (NRP2) antibody program in oncology. Led by Dr. Robert Gemmill, the collaboration seeks to develop therapeutic antibodies targeting specific NRP2 isoforms, particularly in lung cancer, which is characterized by high NRP2 expression correlating with poor outcomes. aTyr aims to leverage this partnership to enhance therapeutic strategies against lung cancer, addressing a significant medical need amid rising drug resistance in aggressive cases.
aTyr Pharma (Nasdaq: LIFE) announced that its President and CEO, Sanjay S. Shukla, will participate in a panel discussion titled, “Immune Modulators to Ameliorate COVID-19” during the ROTH Capital Partners Webinar on October 28, 2020. This webinar will focus on COVID-19 therapeutics in development and aims to explore innovative treatments.
The event is scheduled from 9:00 a.m. to 10:20 a.m. Eastern Time. Registration is available on aTyr's website, and a replay will follow.